Serial QuantiFERON-TB Gold testing in patients with psoriasis treated with ustekinumab.
<h4>Background</h4>There is increasing concern about the risk of latent tuberculosis infection (LTBI) reactivation during the use of biologics for psoriasis. Although ustekinumab had been documented with low risk of tuberculosis, the long-term follow-up of LTBI as determined by QuantiFER...
Saved in:
| Main Authors: | Chuan-Yu Hsiao, Hsien-Yi Chiu, Ting-Shun Wang, Tsen-Fang Tsai |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0184178&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies.
by: Chen-Yu Wu, et al.
Published: (2019-01-01) -
QuantiFERON-TB Gold Plus for screening and monitoring latent tuberculosis infection in spondyloarthritis patients
by: Zehra Ozsoy, et al.
Published: (2025-05-01) -
Performance of QuantiFERON TB in a student population at low risk of tuberculosis
by: Paola Molicotti, et al.
Published: (2011-11-01) -
QuantiFERON-TB supernatant-based biomarkers predicting active tuberculosis progression
by: Haoxin Xu, et al.
Published: (2025-08-01) -
Factors associated with indeterminate QuantiFERON-TB Gold Plus Test results during the COVID-19 pandemic
by: Carla M. Román-Montes, et al.
Published: (2025-01-01)